Development of a biodegradable implant for the delivery of GLP-1 agonists, indicated for the treatment of metabolic syndrome. For the active ingredient, promising results from feasibility and human pharmacokinetic studies are available.
Development of a biodegradable implant for the delivery of GLP-1 agonists, indicated for the treatment of metabolic syndrome. For the active ingredient, promising results from feasibility and human pharmacokinetic studies are available.